

Practitioner's Docket No. MP190-002CP2DV1CNBCN3M

USSN: 10/712,332

Preliminary Amendment**In the Claims:**

Please amend claims 1, 2 and 4. Please cancel claims 3 and 5, and add claims 6-12. This listing of the claims replaces all prior versions and listings of claims in the applications:

1. (Currently Amended) A ~~procoagulant~~ composition comprising a transiently inactive modified form of a blood factor selected from the group consisting of Factor Xa, Factor IXa, activated Protein C, and Factor VIIa, or a polypeptide fragment thereof, wherein the blood factor comprises an inhibitor selected from the group consisting of benzamidines, substituted benzamidines, Kunitz class inhibitors, and an antibody or antibody fragment thereof; which wherein the modified blood factor has been transiently modified to have little or no enzymatic activity.

2. (Currently Amended) A blood factor ~~from the group consisting of Factor Xa, Factor IXa, activated Protein C, and Factor VIIa,~~ which has been modified to extend its half-life in serum wherein said modified form of blood factor generates active factor-blood factor in the presence of serum[.], wherein the modification is selected from the group consisting of polyethylene glycol conjugation and microencapsulation.

3. (Canceled)

4. (Currently Amended) A pharmaceutical composition ~~for use in treating hemophilia~~ which comprises the modified blood factor of claim [[2]]1 in admixture with a pharmaceutically acceptable excipient.

5. (Canceled)

6. (New) The composition of claim 1, wherein the antibody is a monoclonal antibody.

7. (New) The composition of claim 1, wherein the antibody fragment is a Fab fragment.

8. (New) The composition of claim 1, wherein the inhibitor is a Kunitz class inhibitor.

(Page 2 of 4)

Practitioner's Docket No. MP190-002CP2DV1CNBCN3M**USSN: 10/712,332**

9. (New) The composition of claim 8, wherein the inhibitor selected from the group consisting of aprotinin and LACI.
10. (New) The composition of claim 1, wherein the inhibitor is 1,2-bis(5-amidino 2-benzofuranyl)ethane.
11. (New) The pharmaceutical composition of claim 4 for use in treating thrombosis.
12. (New) The composition of claim 11, comprising modified activated Protein C.